Cargando…

Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines

SIMPLE SUMMARY: Effective cancer immunotherapies, with the objective to boost tumor-specific immune responses, is a game-changer in personalized cancer treatment. In immunotherapy, the immune system is exploited to recognize and destroy cancer cells, and this is only possible if a full recapitulatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernardes de Jesus, Bruno, Neves, Bruno Miguel, Ferreira, Manuela, Nóbrega-Pereira, Sandrina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760556/
https://www.ncbi.nlm.nih.gov/pubmed/33266109
http://dx.doi.org/10.3390/cancers12123581
_version_ 1783627360341327872
author Bernardes de Jesus, Bruno
Neves, Bruno Miguel
Ferreira, Manuela
Nóbrega-Pereira, Sandrina
author_facet Bernardes de Jesus, Bruno
Neves, Bruno Miguel
Ferreira, Manuela
Nóbrega-Pereira, Sandrina
author_sort Bernardes de Jesus, Bruno
collection PubMed
description SIMPLE SUMMARY: Effective cancer immunotherapies, with the objective to boost tumor-specific immune responses, is a game-changer in personalized cancer treatment. In immunotherapy, the immune system is exploited to recognize and destroy cancer cells, and this is only possible if a full recapitulation of tumor specific antigens complexity is achieved. Patient-derived induced pluripotent stem cells (iPSCs) share several characteristics with cancer (stem) cells (CSCs). The exploitation of iPSCs as a source of tumor- and patient-specific antigens guiding the immune system against cancer has been addressed recently in mice. Here, we will debate novel findings on the potential implication of cellular reprogramming and iPSCs plasticity for the design of novel cancer immunotherapeutic strategies. ABSTRACT: Despite improvements in cancer therapy, metastatic solid tumors remain largely incurable. Immunotherapy has emerged as a pioneering and promising approach for cancer therapy and management, and in particular intended for advanced tumors unresponsive to current therapeutics. In cancer immunotherapy, components of the immune system are exploited to eliminate cancer cells and treat patients. The recent clinical successes of immune checkpoint blockade and chimeric antigen receptor T cell therapies represent a turning point in cancer treatment. Despite their potential success, current approaches depend on efficient tumor antigen presentation which are often inaccessible, and most tumors turn refractory to current immunotherapy. Patient-derived induced pluripotent stem cells (iPSCs) have been shown to share several characteristics with cancer (stem) cells (CSCs), eliciting a specific anti-tumoral response when injected in rodent cancer models. Indeed, artificial cellular reprogramming has been widely compared to the biogenesis of CSCs. Here, we will discuss the state-of-the-art on the potential implication of cellular reprogramming and iPSCs for the design of patient-specific immunotherapeutic strategies, debating the similarities between iPSCs and cancer cells and introducing potential strategies that could enhance the efficiency and therapeutic potential of iPSCs-based cancer vaccines.
format Online
Article
Text
id pubmed-7760556
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77605562020-12-26 Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines Bernardes de Jesus, Bruno Neves, Bruno Miguel Ferreira, Manuela Nóbrega-Pereira, Sandrina Cancers (Basel) Review SIMPLE SUMMARY: Effective cancer immunotherapies, with the objective to boost tumor-specific immune responses, is a game-changer in personalized cancer treatment. In immunotherapy, the immune system is exploited to recognize and destroy cancer cells, and this is only possible if a full recapitulation of tumor specific antigens complexity is achieved. Patient-derived induced pluripotent stem cells (iPSCs) share several characteristics with cancer (stem) cells (CSCs). The exploitation of iPSCs as a source of tumor- and patient-specific antigens guiding the immune system against cancer has been addressed recently in mice. Here, we will debate novel findings on the potential implication of cellular reprogramming and iPSCs plasticity for the design of novel cancer immunotherapeutic strategies. ABSTRACT: Despite improvements in cancer therapy, metastatic solid tumors remain largely incurable. Immunotherapy has emerged as a pioneering and promising approach for cancer therapy and management, and in particular intended for advanced tumors unresponsive to current therapeutics. In cancer immunotherapy, components of the immune system are exploited to eliminate cancer cells and treat patients. The recent clinical successes of immune checkpoint blockade and chimeric antigen receptor T cell therapies represent a turning point in cancer treatment. Despite their potential success, current approaches depend on efficient tumor antigen presentation which are often inaccessible, and most tumors turn refractory to current immunotherapy. Patient-derived induced pluripotent stem cells (iPSCs) have been shown to share several characteristics with cancer (stem) cells (CSCs), eliciting a specific anti-tumoral response when injected in rodent cancer models. Indeed, artificial cellular reprogramming has been widely compared to the biogenesis of CSCs. Here, we will discuss the state-of-the-art on the potential implication of cellular reprogramming and iPSCs for the design of patient-specific immunotherapeutic strategies, debating the similarities between iPSCs and cancer cells and introducing potential strategies that could enhance the efficiency and therapeutic potential of iPSCs-based cancer vaccines. MDPI 2020-11-30 /pmc/articles/PMC7760556/ /pubmed/33266109 http://dx.doi.org/10.3390/cancers12123581 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bernardes de Jesus, Bruno
Neves, Bruno Miguel
Ferreira, Manuela
Nóbrega-Pereira, Sandrina
Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines
title Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines
title_full Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines
title_fullStr Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines
title_full_unstemmed Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines
title_short Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines
title_sort strategies for cancer immunotherapy using induced pluripotency stem cells-based vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760556/
https://www.ncbi.nlm.nih.gov/pubmed/33266109
http://dx.doi.org/10.3390/cancers12123581
work_keys_str_mv AT bernardesdejesusbruno strategiesforcancerimmunotherapyusinginducedpluripotencystemcellsbasedvaccines
AT nevesbrunomiguel strategiesforcancerimmunotherapyusinginducedpluripotencystemcellsbasedvaccines
AT ferreiramanuela strategiesforcancerimmunotherapyusinginducedpluripotencystemcellsbasedvaccines
AT nobregapereirasandrina strategiesforcancerimmunotherapyusinginducedpluripotencystemcellsbasedvaccines